Brad Rosbrook

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

Medicine, Oncology, Pharmacology +8

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Robert J. Motzer, Bernard Escudier, Piotr Tomczak et al. · The Lancet Oncology · 2013 · 745 citations

Medicine, Oncology, Pharmacology +10

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Thomas E. Hutson, Vladimir Lesovoy, V.P. Stus et al. · The Lancet Oncology · 2013 · 405 citations

Medicine, Oncology, Pharmacology +13

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov et al. · The Lancet Oncology · 2018 · 368 citations

Medicine, Oncology, Pharmacology +10